Guangzhou Bio-gene Technology Co., Ltd
Clinical trials sponsored by Guangzhou Bio-gene Technology Co., Ltd, explained in plain language.
-
New CAR-T therapy targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study tests a new treatment called CAR-T cell therapy for people with advanced colorectal cancer that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins (CDH17 and GUCY2C) found on cancer cells. The goal is…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Engineered immune cells take on lupus and arthritis in new trial
Disease control Recruiting nowThis study tests a new treatment called CD19-BCMA CAR-T cell therapy for people with connective tissue diseases like lupus, rheumatoid arthritis, and scleroderma. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goa…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Engineered immune cells take on Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check if the treatment i…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 19, 2026 11:47 UTC